The race for a vaccine


As soon as Pfizer and its partner BioNTech announced that their Covid-19 vaccine has 95% efficacy, stock markets across the globe went berserk to price in an economic recovery. The damage on rubber glove counters was real, with a free fall in their share prices since last week, before bargain hunters came in to bottom fish yesterday.

IT WAS perhaps the only single piece of news that investors around the world wanted to hear. As soon as Pfizer and its partner BioNTech announced that their Covid-19 vaccine has 95% efficacy, stock markets across the globe went berserk to price in an economic recovery.

The damage on rubber glove counters was real, with a free fall in their share prices since last week, before bargain hunters came in to bottom fish yesterday.

Subscribe or renew your subscriptions to win prizes worth up to RM68,000!

Monthly Plan

RM13.90/month

Annual Plan

RM12.33/month

Billed as RM148.00/year

1 month

Free Trial

For new subscribers only


Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
   

Next In Business News

Step back and watch
Bull waits for liquidity to return
Magnum can strike it big again
All sails set for MISC-Bumi Armada merger
Dicey days for chip makers
After a homeowner passes
A stinky nuisance: When septic tanks burst
Decarbonising cement: Are we ready?
Ringgit to trade in tight range of 4.46-4.48 versus US dollar next week
Shedding light on power sector prospects

Others Also Read